Avant Diagnostics (OTC: ADVX) is a leading medical
technology company focused on advancing innovative solutions that improve upon
the ways we screen for ovarian cancer. ADVX’s energy and resources aim to bring
to market innovative diagnostic tests based upon the completion of the human
genome sequencing project. The company works at developing a sophisticated
screening test for diagnosing ovarian cancer using OvaDx® – a unique
large-panel biomarker screening test for this deadly disease.
OvaDx is an advanced diagnostic test used specifically for
measuring the activation of the immune system in response to ovarian tumor cell
development. Patient sera are used in conjunction with OvaDx microarrays, which
enable binding between proteomic biomarkers in the patient samples and capture
agents on the microarrays. In this process, the microarrays are washed and scanned
to produce a digital readout for each serum sample. From this point, the data
are quantified and analyzed using software to produce the results of the test.
ADVX’s discovery path comes by way of ten years of genetic
and physiological research. Avant Diagnostics concentrates on leveraging the
human immune system for early detection. As a result, OvaDx delivers a large
panel of refined markers for high sensitivity. The company’s proprietary OvaDx
markers and kits include patented manufacturing technology, as well as a
worldwide license. Following FDA 510(k) clearance, the company plans to license
OvaDx for sale. Avant’s business plan looks to use its position as a public
company to expand its portfolio of diagnostic tests going forward.
Genetic research is predominantly centered on identifying
the variations of the specific genes in the genome. These variations define
individual characteristics, including disease states or a statistical
propensity for disease. The implications are far-reaching and impact not only
the research community, but also the individual patients and care providers.
Diagnostic tests that detect diseases very early in their progression will
provide options for earlier treatments that show promise of improving quality
of life and prognosis by delaying or preventing disease progression. It has
been noted that medical providers will realize major cost savings by avoiding
costly treatments at late stages.
For more information, visit www.avantdiagnostics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment